Inclusion Criteria:

          -  Histologic proof of cancer for which no standard therapy is available, and which shows
             no staining for RB by IHC.

          -  Spirometry with at least 70% of predicted volumes (including FEV1). A left ventricular
             ejection fraction (LVEF) of 45% or more. All patients will have a screening 2-D
             Echocardiogram as part of eligibility screening.

          -  Patients must have adequate physiologic reserve as evidenced by:

               -  Zubrod Performance Status (PS) of </= 2; or 3 if of recent onset (i.e. < 2 weeks)
                  and if the compromised performance status is related to uncontrolled pain which
                  is expected to come under control by means of improved pain management.

               -  Laboratory values meeting the following criteria:

                    -  Absolute neutrophil count >/= 1,200/mm3

                    -  Platelet count >100,000/mm3.

                    -  AST and ALT </= 3x the upper limit of normal

                    -  Conjugated bilirubin </= 1.5 mg/dL (or total bilirubin </= 2.5 mg/dL)

                    -  Native kidney function producing creatinine clearance (either measured or
                       estimated by Cockcroft formula) of at least 40 mL/min. Cockcroft formula:
                       CLcr = [(140-age) • wt(kg)]/[72 •Creat (mg/dL)] (For females, multiply by
                       0.85)

                    -  Hemoglobin >/= 10.0 g/dL without transfusion support

                    -  White blood cell count > 3.0 k/mm3

                    -  PT and aPTT each < 1.5 times the upper limit of normal.

          -  Women of child-bearing potential must have a negative pregnancy test.

          -  Male and female patients reproductive potential must agree to use measures to avoid
             pregnancy throughout the study and for 3 months following discontinuing study drug.

          -  Patients must have recovered from any previous therapy side effects or toxicities
             prior to initiating protocol study infusions.

          -  Life expectancy > 12 weeks.

          -  Organ function </= grade 1.

          -  Age of </= 18 years.

        Exclusion Criteria:

          -  Some prior cancer therapies are not consistent with eligibility; specifically:

               -  At least 30 days must have elapsed since any prior experimental therapy

               -  At least 6 weeks must have elapsed since prior systemic mitomycin C

               -  At least 8 weeks must have elapsed since any dose of Strontium-89

               -  At least 4 weeks must have elapsed since prior Sm-153 lexidronam (Quadramet™)

               -  At least 4 weeks must have elapsed since prior radiotherapy

               -  Any prior exposure to gene vector delivery products

          -  Pregnancy or lactation

          -  Serious concurrent medical illness that in the opinion of the investigator would
             compromise patient safety or preclude accurate assessment of outcome.

          -  Patients with the following manifestations of cardiovascular disease are excluded:

               -  Myocardial infarction (MI) within the previous six months, or patients with left
                  ventricular ejection fraction of less than 45% secondary to a more remote MI.

               -  Any history of CVA or TIA in previous six months

               -  New York Heart Association grade 2 or greater congestive failure

               -  Unstable angina defined as angina (or anginal equivalent) 2 or more times per
                  week despite medical therapy.

               -  Echocardiographic evidence of pulmonary hypertension.

               -  Diastolic dysfunction felt to contribute to any clinical sign or symptom.

               -  Uncontrolled hypertension, defined as systolic BP >140 or diastolic >90 despite
                  therapy.

          -  Serious concurrent psychiatric disorder that in the opinion of the investigator would
             compromise patient safety or preclude accurate assessment of outcome.

          -  Supraphysiologic doses of glucocorticoids (defined as > 30 mg of hydrocortisone per
             day or > 7.5 mg of Prednisone per day, or equivalent doses of other agents) or
             exposure to other immunosuppressive medications in the previous 30 days.

          -  Requirement for anticoagulant therapy other than low intensity treatment to maintain
             patency of central venous catheters.

          -  Treatment with antibiotics for proven infection within 1 week prior to study entry or
             signs and symptoms consistent with an active infection or fever > 38.1 C.